TrialBlood advances2023

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.

Bradley Haverkos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.